BioAtla Inc (NAS:BCAB)

Q3 2025 Bioatla Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $32.99 (-4.09%)

Transcript 10-Q8-K

Key Points

Positve

BioAtla Inc (BCAB) is in advanced stages of finalizing a strategic transaction with a potential partner by year-end.
The company achieved FDA alignment on the phase three OSV registrational trial design for treating second-line plus oropharyngeal squamous cell carcinoma (OPSCC).
BioAtla Inc (BCAB) presented compelling data from multiple programs, validating the potential of their CAB platform for treating difficult cancers.
A development milestone was achieved under a license agreement with Context Therapeutics, providing non-dilutive capital and validating the CAB T-cell engager platform.
The company estimates worldwide peak sales of their product for OPSCC to be approximately $800 million, with the total market projected to reach $3 billion by 2032.

Negative

BioAtla Inc (BCAB) reported a net loss of $15.8 million for the third quarter of 2025, an increase from the $10.6 million loss in the same quarter of 2024.
The company's cash and cash equivalents stood at $8.3 million as of September 30, 2025, indicating limited financial resources.
There was a $2.1 million non-cash loss on warrant liability recorded in the third quarter of 2025.
Research and development expenses decreased by $6.9 million due to reduced program development costs and workforce reduction, which may impact future innovation.
General and administrative expenses decreased by $1.7 million, primarily due to reduced personnel costs, which could affect operational efficiency.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCAB.OQ - Bioatla Inc
Q3 2025 Bioatla Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone and welcome to today's Bio Atla 3rd quarter 2025 earnings call.

This time all participants were in a listen-only mode.

Later you may have the opportunity to ask questions during the question-and-answer session.

I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Julie Miller with Lifesy Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good afternoon everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO, and co-founder,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.